CHRS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
14.3M
-0.2%
14.3M
+16.2%
12.3M
-3.4%
12.7M
+10.2%
11.6M
Cost of Revenue
4.1M
-3.5%
4.2M
+11.2%
3.8M
-5.7%
4.0M
+8.7%
3.7M
Gross Profit
10.2M
+1.2%
10.1M
+18.5%
8.5M
-2.4%
8.7M
+10.9%
7.8M
Operating Expenses
43.8M
+3.4%
42.4M
-5.0%
44.6M
-18.2%
54.6M
+4.6%
52.2M
R&D
22.6M
+5.4%
21.4M
-0.5%
21.5M
-30.4%
31.0M
+13.7%
27.3M
SG&A
21.2M
+1.3%
21.0M
-9.3%
23.1M
-2.1%
23.6M
-5.3%
24.9M
Operating Income
-33649000
-4.1%
-32331000
+10.6%
-36151000
+21.2%
-45880000
-3.5%
-44333000
EBITDA
-32796000
-4.2%
-31469000
+10.8%
-35270000
+21.6%
-44984000
-3.7%
-43367000
Net Income
-39334000
-90.7%
-20631000
+46.2%
-38327000
-1.8%
-37643000
-5.9%
-35531000
EPS (Basic)
$-0.25
-92.3%
$-0.13
+53.6%
$-0.28
+9.7%
$-0.31
+0.0%
$-0.31
EPS (Diluted)
$-0.25
-92.3%
$-0.13
+53.6%
$-0.28
+9.7%
$-0.31
+0.0%
$-0.31
Shares (Diluted)
155.0M
+0.1%
154.8M
+13.5%
136.4M
+13.3%
120.4M
+3.6%
116.2M
Coherus Oncology (CHRS) — Financials